SG2918 For Advanced Malignant Tumors

1. Histologically or cytologically documented advanced malignant tumors that is refractory/relapsed to standard therapies;

2. Adequate organ function;

3. ECOG Performance Status score of 0 or 1;

4. Must have at least one measurable lesion according to RECIST Version1.1;

5. Toxicity caused by prior anti-tumor therapy recovered to Grade 0 to 1 (CTCAE 5.0);

6. Must have an effective contraception during the study, starting with the Screening Visit through 7 months after the last dose of study intervention.

1. Has active central nervous system metastatic lesions;

2. Has Active autoimmune disease requiring systemic therapy within the past 2 years;

3. Has Grade 2 and above peripheral neuropathy;

4. Has an active infection requiring systemic therapy;

5. Has a history of any of the following cardiovascular conditions within 6 months of dosing: myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, coronary artery bypass graft, pulmonary embolism, etc; has New York Heart Association (NYHA) Class II and above congestive heart failure; LVEF<50%;

6. Has a history of hypertensive crisis or hypertensive encephalopathy; Uncontrolled hypertension though standard treatment within 14 days before the first dose (systolic blood pressure≥160 mmHg and/or diastolic blood pressure≥100mmHg);

7. Has known human immunodeficiency virus (HIV) and/or hepatitis B or C infections;

8. Has a history of potent CYP3A4 inhibitor with 2 weeks;

9. Has received systemic anticancer therapy, radiotherapy, or surgery within 4 weeks before the start of study treatment;

10. Have received previous treatment targeted LILRB4 or MMAE experiencing serious adverse events;

11. Have received previous immunotherapy experiencing serious adverse events that leading to permanent discontinuation;

12. Have received systemic corticosteroids (equivalent dose > 10 mg/day of prednisone) or other immunosuppressive drugs within 14 days prior to the first dose;

13. Has had a severe hypersensitivity reaction to treatment with a monoclonal antibody (mAB) and or any components of the study intervention;

14. Any live vaccine within 28 days prior to the first dose;

15. Has a history of interstitial lung disease or active pneumonia or tracheal fistula; uncontrolled pleural, abdominal and pericardial effusion;

16. Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 year.